UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): July 2, 2007
BIOJECT MEDICAL TECHNOLOGIES INC.
(Exact name of registrant as specified in its charter)
Commission File Number: 0-15360
Oregon |
| 93-1099680 |
(State or other jurisdiction of incorporation |
| (I.R.S. Employer Identification No.) |
or organization) |
|
|
|
|
|
20245 SW 95th Avenue |
|
|
Tualatin, Oregon |
| 97062 |
(Address of principal executive offices) |
| (Zip Code) |
|
|
|
Registrant’s telephone number, including area code: (503) 692-8001 | ||
|
|
|
Former name or former address if changed since last report: | ||
No Change |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 5.02 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
(a) On July 2, 2007, the Board of Directors of Bioject Medical Technologies Inc. (the “Company”) approved amendments to the Company’s Second Amended and Restated Bylaws (the “Bylaws”) to clarify the Company’s ability to issue and transfer uncertificated shares.
The foregoing description of the amendments to the Bylaws is qualified in its entirety by reference to the full text of the Second Amended and Restated Bylaws, as amended, which is filed as Exhibit 3.1 to this Current Report on Form 8-K and incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits
The following exhibit is filed herewith and this list is intended to constitute the exhibit index.
Exhibit No. |
| Description |
|
|
|
3.1 |
| Second Amended and Restated Bylaws of the Registrant, as amended |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: July 5, 2007 | BIOJECT MEDICAL TECHNOLOGIES INC. |
| |
| (Registrant) |
| |
|
|
| |
|
|
| |
| /s/ CHRISTINE M. FARRELL |
|
|
| Christine M. Farrell |
| |
| Vice President of Finance |
| |
| (Principal Financial and Accounting Officer) |
| |